创响生物:IMG-007针对中重度特应性皮炎的2b期临床试验完成首例患者给药

市场资讯
Jul 02

  炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!

7月2日,创响生物(Inmagene Biopharmaceuticals)宣布,IMG-007在治疗中重度特应性皮炎(AD)患者中的2b期国际多中心、剂量探索研究(ADAPTIVE研究)中实现首例患者给药。预计该2b期ADAPTIVE临床试验的顶线结果将于2026年第四季度公布。据创响方面介绍,IMG-007是一种人源化抗OX40单克隆抗体,采用皮下注射给药方式。

海量资讯、精准解读,尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10